26.03.2024 / Deals & Cases

Deal: Wenger Vieli advised OneTwenty on its seed funding

Wenger Vieli advised OneTwenty, a Zurich-based medtech startup specializing in personalized diabetes management solutions, on all Swiss legal matters. The round was led by Cologne-based venture capital firm Dieter von Holtzbrinck Ventures and also included Tiny Supercomputer Investment Company as well as experienced healthtech investor Tim Jürgens.

The funds are intended for the commercialization of OneTwenty's bioX technology, an advanced machine learning solution for diabetes care, and enables the company to expand its medtech and pharmaceutical partnerships.

Founded in 2022, OneTwenty is pioneering in the development of algorithms to enhance diabetes device functionality. Its proprietary technology, bioX, is designed to understand the complexities of human metabolism, offering a new level of personalized diabetes care through integration with insulin pumps, smart pens, and blood glucose sensors.

The team was led by Michael Baier (Partner, Venture Capital / M&A) and included Dominique Mattmann (Associate, Venture Capital / M&A) as well as Kianoush Sadeghi (Associate, Venture Capital / M&A).

ContactMichael Baier +41 58 958 55 73  

Team Involved

Baier Michael



Mattmann Dominique


Senior Associate

Sadeghi Kianoush